Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 913-660-8 | CAS number: -
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- (Q)SAR
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
Test material
- Reference substance name:
- Reaction mass of glycerol and N-[3-(dimethylamino)propyl]stearamide and N-[3-(dimethylamino)propyl]docosanamide
- Molecular formula:
- C21 H50 N O C23 H54 N O C25 H58 N O C27 H62 N O
- IUPAC Name:
- Reaction mass of glycerol and N-[3-(dimethylamino)propyl]stearamide and N-[3-(dimethylamino)propyl]docosanamide
- Test material form:
- solid: flakes
Constituent 1
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- Typically, the substance could be absorbed in small intestine with low rate and would not pass the BBB easily and rapidly
- Type:
- distribution
- Results:
- This substance could bind on plasma proteins with high binding rate but not with the serum proteins
- Type:
- metabolism
- Results:
- This substance would be metabolized by N-dealkylation, N-oxidation, and hydroxylation.
- Type:
- excretion
- Results:
- Water-soluble metabolites will be produced for excretion through urine
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- The predicted ADMET_Absorption_T2_2D is 9.911, level: 2. Level 2 represents this substance would have a weak absorption in small intestinal. The result is accordant with the prediction of ACD/ADME.
- Details on distribution in tissues:
- The predicted ADMET_AlogP98: 7.541, level2. Level 2 represents this substance would have a binding rate more than 95% with plasma proteins. According to this DS/ADMET prediction, this compound would have high binding rate with plasma proteins. The result is consistent with the prediction of ACD/ADME.
Metabolite characterisation studies
- Metabolites identified:
- not measured
- Details on metabolites:
- Typically, this substance could be absorbed in small intestine with low rate and would not pass the BBB easily and rapidly. Furthermore,it could bind on plasma proteins with high binding rate but not with the serum proteins. Meanwhile, it may be an inhibitor but not a substrate of P-gp. On the other hands, it would not be an inhibitor of CYP450.
Bioaccessibility (or Bioavailability)
- Bioaccessibility (or Bioavailability) testing results:
- The substance has a moderate oral bioavailability of 30~70%.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
